Please login to the form below

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Moderna and CytomX to partner in deal worth up to 1.2bn

CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.

Latest news

Regeneron and CytomX partner to create conditional bispecific cancer therapies

Regeneron and CytomX Therapeutics have entered into a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies, the companies announced. ... CytomX's pipeline currently comprises seven
Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies. Gilead Sciences (Gilead) has teamed up with MacroGenics – a biopharmaceutical company that specialises on the development and commercialisation of innovative monoclonal ... therapeutics
AstraZeneca to present new oncology data at AACR

The company will be introducing its next wave of IO therapies, sharing the first clinical results for MEDI5752 – a novel bispecific antibody, which simultaneously targets immune checkpoint proteins in solid tumours. ... Bispecific antibodies are a
Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen already has its own antibody technology – known as BiTE – which enables the identification and development of bispecific T cell engager antibodies. ... TNB-585 is a bispecific T cell-engager being evaluated for the treatment of metastatic
Genmab enters oncology collaboration with Bolt Biotherapeutics

The companies will evaluate Genmab’s antibodies and bispecific antibody engineering technologies alongside Bolt’s immune-stimulating antibody conjugate (ISAC) technology platform. ... We are delighted to be collaborating with the Genmab team and to

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

ASH 2022: bad blood but big advances

Multiple myeloma was a major focus, with data presentations on emerging and approved bispecific antibodies and CAR-T therapies showcasing promising approaches for heavily pre-treated patients. ... One particular session on bispecific antibodies attracted
Putting the ovation into innovation: trends from ESMO

toxicity, including innovative bispecific monoclonal antibodies and Bi-specific T-cell engagers.
European biotech: a new generation of leaders emerges

It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug
Deal Watch December 2016

511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.
Deal Watch September 2016

In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

F-star hires ex-BMS immuno-oncology leader

Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.